指南与共识药物不良反应与药物警戒特殊人群用药

COVID-19及疫苗接种对临床试验中疑似急性药物性肝损伤检测、评估与管理的影响:IQ DILI倡议共识建议

The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.
指南 / 共识 · Drug Saf · 2025-08-05

IQ DILI倡议汇集学术界、监管机构和产业界专家,通过广泛文献综述和结构化讨论,针对COVID-19、其治疗及疫苗接种对临床试验中疑似急性药物性肝损伤(DILI)检测、评估和管理的影响提出共识建议。共识强调COVID-19检测应纳入DILI因果关系评估,并应主动询问疫苗接种史,以避免过早终止研究药物。

要点

  • COVID-19检测应作为DILI因果关系评估的一部分,阳性结果可避免过早终止研究药物。
  • 应主动询问临床试验参与者的疫苗接种史,因患者可能忽略报告。
  • COVID-19治疗可能引起肝损伤或改变药代动力学,需关注。

核心结论

  • COVID-19检测应纳入DILI因果关系评估,阳性检测结果可能防止过早终止研究药物。
  • 鉴于临床试验参与者可能未将疫苗接种列入病史,当筛查期间肝检验异常及作为DILI因果关系评估的一部分时,应具体询问其接种情况。

研究设计与样本

  • IQ DILI倡议由学术界、监管机构和产业界专家组成,进行了广泛文献综述,并在IQ DILI产业成员、监管机构及肝病学和DILI学术专家之间进行了结构化讨论。

主要发现

  • 非住院COVID-19患者的肝脏相关表现高度多样,肝损伤证据可能在COVID-19症状消退且检测阴性后出现。
  • COVID-19治疗可能引起肝损伤或改变药代动力学。
  • COVID-19疫苗接种与罕见但明确的肝毒性相关,通常符合药物诱导的自身免疫样肝炎,但其他表现、严重程度、潜伏期和消退时间也有报道。
  • 肝损伤发生于mRNA疫苗和病毒载体疫苗,以及有或无潜在自身免疫或肝脏疾病的个体中。

临床怎么用

  • 药物开发者和研究者在试验期间应了解COVID-19、其治疗及COVID-19疫苗接种相关的潜在肝脏表现,因其可能影响研究资格和因果关系评估。
  • COVID-19检测应被视为DILI因果关系评估的一部分,阳性检测可能防止过早终止研究药物。
  • 当筛查期间肝检验异常及作为DILI因果关系评估的一部分时,应具体询问临床试验参与者的疫苗接种情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While the acute impact of the coronavirus disease 2019 (COVID-19) pandemic has waned, implications for clinical trials remain. In particular, guidance for evaluation of elevated liver tests due to COVID-19, its treatments, and COVID-19 vaccination is lacking. The IQ DILI Initiative, composed of experts from academia, regulatory agencies, and industry herein propose recommendations to address this gap. Extensive literature review was conducted and structured discussions were held between IQ DILI industry members, regulators, and academic experts in hepatology and DILI. Liver-related manifestations in nonhospitalized patients with COVID-19 are highly varied. Evidence of liver injury may occur after COVID-19 symptoms resolve and testing is negative. Treatments for COVID-19 may cause liver injury or alter pharmacokinetics. COVID-19 vaccination has been associated with rare but clear hepatotoxicity, typically consistent with drug-induced autoimmune-like hepatitis, although other presentations, severity, latency, and time to resolution have been reported. Liver injury occurred with mRNA and viral vector vaccines, and in individuals with and without underlying autoimmune or liver diseases. Drug developers and investigators should be aware of the potential liver-related manifestations related to COVID-19, its treatments, and COVID-19 vaccination, as this may impact study eligibility and causality assessment during a trial. COVID-19 testing should be considered part of DILI causality assessment, as a positive test may prevent premature termination of the investigational drug. Since clinical trial participants may not consider vaccinations in their medical history, specific inquiry about their receipt is important when liver tests are abnormal during screening and as part of DILI causality assessment.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Palmer M, Seekins D, Avigan M, et al. The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative. Drug Saf. 2025. PMID: 40762948. doi:10.1007/s40264-025-01591-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。